H-1B sponsorship profile: Innovative Cellular Therapeutics, Inc. Across U.S. Department of Labor LCA disclosures, Innovative Cellular Therapeutics, Inc filed 11 Labor Condition Applications covering 13 H-1B worker positions between fiscal year 2023 and fiscal year 2025. The employer’s DOL certification rate sits at 100% (11 certified of 11 filed), a useful proxy for how cleanly their prevailing-wage attestations pass the Labor Department’s preliminary review before USCIS adjudication.

Compensation spread. Offered wages on Innovative Cellular Therapeutics, Inc’s H-1B petitions range from $63,440 at the low end to $142,000 at the high end, with a petition-weighted average of $83,707. That range reflects the mix of occupations the company sponsors, led by Quality Control Manager (3 petitions at $82,659 avg), followed by Cell Production Specialist and Validation & Regulatory Affairs Engineer. H-1B salaries reported on LCAs must meet or exceed the DOL prevailing wage for the role and worksite, so the spread also tracks wage-level geography and seniority.

Geographic footprint. Innovative Cellular Therapeutics, Inc is headquartered in Rockville, MD under NAICS code 5417, and places H-1B workers across 1 state, most heavily in MD. Combined, these signals give a granular view of how one employer uses the H-1B program, volume, approval cleanliness, wage posture, and where the jobs actually sit on the map.

Where Innovative Cellular Therapeutics, Inc ranks. By H-1B petition volume, Innovative Cellular Therapeutics, Inc is #15,566 of 119,880 employers nationally and #274 of 2,045 employers headquartered in MD. Both ranks are computed live from the same underlying petition counts, not a separate estimate.